Award recordCONTRACT

APO-PHARMA USA, INC.

PIID VA26018J2227· VHA· 260-NETWORK CONTRACT OFFICE 20 (36C260)· 6505 · DRUGS AND BIOLOGICALS· FY2018· $114,763 net obligations· UEI JDSKMX3AW5M5· FL

Description

FERRIPROX (DEFERIPRONE) 500MG DE-OBLIGATION

Base award description: FERRIPROX (DEFERIPRONE) 500MG

First action · last action
2017-10-01 · 2020-04-21
Transactions
2
First transaction's obligation
$205,193
Base + all options value (sum of deltas)
$114,763
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
—
Offers received
—
SDVOSB flag on record
No
Parent IDV
VA797P14A0009
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING

Modification chain · 2 transactions

Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.

$205,193$0Base award · 2017-10-01 · this action $205,193 · running total $205,193Modification P00001 · 2020-04-21 · this action -$90,430 · running total $114,763
  • Base2017-10-01+$205,193= $205,193
  • Mod P000012020-04-21-$90,430= $114,763
TransactionAction dateThis action (delta)Running totalDescription on this transaction
Base2017-10-01+$205,193$205,193FERRIPROX (DEFERIPRONE) 500MG
Mod P00001· CLOSE OUT2020-04-21−$90,430$114,763FERRIPROX (DEFERIPRONE) 500MG DE-OBLIGATION

Related awards · 11

Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.

Other VA awards to the same recipient (UEI JDSKMX3AW5M5)

AwardOffice · PSC / listingNet obligationsFY
36C24520F0484245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS$50,449FY2020
36C24820F0107248-NETWORK CONTRACT OFFICE 8 (36C248) · 6505 · DRUGS AND BIOLOGICALS$14,407FY2020
36C24520F0248245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS$53,556FY2020
36C24220F0122242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS$17,852FY2020
36C24519F0803245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS$44,630FY2019
36C24219F0433242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS$0FY2019

Other recipients under 6505 from 260-NETWORK CONTRACT OFFICE 20 (36C260) (most recent first)

AwardRecipientOfficeNet obligationsFY
36C26026F0379COSETTE PHARMACEUTICALS, INC.260-NETWORK CONTRACT OFFICE 20 (36C260)$3,466FY2026
36C26026P0671MCKESSON PLASMA AND BIOLOGICS LLC260-NETWORK CONTRACT OFFICE 20 (36C260)$18,262FY2026
36C26026F0349AGIOS PHARMACEUTICALS, INC.260-NETWORK CONTRACT OFFICE 20 (36C260)$73,080FY2026
36C26026F0306BRACCO DIAGNOSTICS INC.260-NETWORK CONTRACT OFFICE 20 (36C260)$337,422FY2026
36C26026F0298PROGENICS PHARMACEUTICALS INC260-NETWORK CONTRACT OFFICE 20 (36C260)$469,134FY2026

Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA26018J2227_3600_VA797P14A0009_3600 · retrieved 2026-09-26.